Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124965 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT04124965 is a Phase 3 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 71 participants.
The verdict
NCT04124965, a Phase 3 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
Interventions
- DRUG Rozanolixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2019-10-29 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04124965
The ClinicalTrials.gov registry entry for NCT04124965 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rozanolixizumab is the first listed.
NCT04124965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04124965 about?
NCT04124965 is a clinical study titled "A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis". The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
What is the current status of trial NCT04124965?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2019-10-29. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT04124965?
The interventions under investigation include: Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT04124965?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.